Charles River Labs stock holds near fresh 52-week high after strong Q2 earnings
Published on 08/21/2026 at 16:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Charles River Laboratories International, Inc. (ISIN US1591881009) stock is trading close to its recent 52-week high in late August 2026, supported by a strong Q2 2026 earnings beat and a raised full-year earnings outlook. Per recent market data as of August 20, 2026, the shares climbed intraday to a new 52-week peak of $294.68 while holding near the $290.00 region on the New York Stock Exchange in the prior close.
Q2 2026 earnings beat and guidance raise
According to an earnings summary reported by IT Boltwise, Charles River Laboratories delivered Q2 2026 revenue of about $1.0 billion, slightly below the prior-year quarter but ahead of analyst estimates that were cited around $976 million. The IT Boltwise Q2 2026 article on Charles River Laboratories notes that this top-line performance combined with a meaningful earnings surprise.
On the bottom line, the same Q2 2026 overview highlights that non-GAAP EPS reached $3.02, compared with a consensus range of $2.74 to $2.77. That implies an earnings beat of at least $0.25 per share against the upper end of the cited analyst expectations, underlining that profitability came in stronger than the market had anticipated.
The company also raised its full-year 2026 guidance for adjusted EPS. As summarized in the IT Boltwise piece, management now expects non-GAAP EPS between $11.15 and $11.45 for 2026. With a midpoint of $11.30, this revised range sits above earlier assumptions referenced in the same dataset, signaling improved confidence in earnings power for the rest of the year.
Operational momentum is visible in the Discovery and Safety Assessment segment, where a Book-to-Bill ratio of 1.19 was reported for Q2 2026. The article emphasizes that this ratio has remained above 1.0 for three consecutive quarters, indicating that new orders have consistently exceeded revenue and that the backlog in this core preclinical services business continues to build.
Shares trade close to a new 52-week high
The Q2 2026 beat and guidance raise have translated into a strong share-price trend. IT Boltwise reports that Charles River Laboratories shares reached a new 52-week high of $294.68 on August 20, 2026, with the stock trading near that level during the session and closing the prior day at $290.00.
An earlier news summary on Ad-hoc News describes the same 52-week-high breakout, noting that Charles River Labs stock pushed to $294.68 and was recently quoted around $294.93 in intraday trading on August 20, 2026. The Ad-hoc News report on Charles River Labs stock 52-week high also points out that the shares last closed at $290.00 on August 19, 2026 before extending toward the new high in the following session.
MarketScreener data for the CBOE listing shows Charles River Laboratories with a last quoted level of $291.48 as of the close on August 20, 2026, representing a daily gain of 0.58 percent and a year-to-date advance of 3.67 percent. The MarketScreener static price chart for Charles River Labs further highlights a 45.99 percent increase from the start of the year, underscoring the strength of the rally in 2026.
An institutional-trading alert from MarketBeat notes that Charles River Laboratories stock opened at $292.97 on August 21, 2026. The MarketBeat filing alert on Charles River Laboratories also references a price of $292.97 during recent trading, consistent with the stock holding just below its newly set 52-week high.
From a valuation perspective, MarketScreener lists a price-to-earnings ratio of 78x for Charles River Laboratories at the $291.48 quote as of August 20, 2026. The MarketScreener financials overview for Charles River Laboratories associates this multiple with the current earnings base, suggesting that investors are willing to pay a premium for the companys growth and service positioning in preclinical research.
Analyst consensus and institutional positioning
Recent coverage summarized by MarketBeat indicates that Charles River Laboratories shares are supported by an analyst consensus rating described as Moderate Buy. The same overview states that twelve analysts rate the stock as Buy, three as Hold, and one as Sell, with an average price target of $255.65. The MarketBeat alert on Charles River Laboratories trading and analyst data notes that institutional investors own 98.91 percent of the float, highlighting the companys strong presence in professional portfolios.
That average target of $255.65 sits materially below the latest trading region near $290.00 to $295.00. The Ad-hoc News summary points to a separate consensus target of $281.00 cited in earnings and news datasets, showing that even the higher target level remains beneath the current share price. In that earlier snapshot, a $290.00 close on August 19, 2026 represented a 3.10 percent premium to the $281.00 target, while the most recent quotes further extend the gap between consensus valuation metrics and the market price.
The same Ad-hoc News piece references a GF Value intrinsic estimate of $194.35 applied in one valuation framework, compared with the $290.00 closing price. That contrast implies that Charles River Laboratories stock was trading roughly 49 percent above that intrinsic benchmark as of August 19, 2026, illustrating the strength of investor enthusiasm relative to more conservative valuation models.
Institutional activity remains active around the current levels. The MarketBeat filing alert notes that Madison Asset Management LLC disclosed a position amounting to $3.81 million in Charles River Laboratories International, adding to the broader institutional footprint at a time when the stock is trading close to its 52-week high. Such flows show that professional investors are still allocating capital to the name despite the elevated price-to-earnings ratio and the premium versus several valuation references.
Momentum and recent insider transactions
Momentum in Charles River Laboratories stock is also visible in longer-term performance metrics. A Zacks news article highlights that the shares gained 88.6 percent over the prior year, framing the company as a strong wealth creator for shareholders during that period. The Zacks analysis of Charles River Laboratories stock rally attributes this move to healthy fundamentals and solid growth opportunities in the companys service lines.
In parallel with the price appreciation, recent insider activity has occurred at levels close to the 52-week high. Investing.com reports that a Charles River Labs executive vice president sold shares valued at $599,710 while the stock traded near a 52-week high of $294.56, after an 82 percent return over the past year. The Investing.com note on Charles River Labs executive share sale situates this transaction in a context of strong price momentum, although the position change does not alter the broader institutional ownership pattern referenced in other datasets.
These momentum and insider signals complement the Q2 2026 earnings beat and guidance raise, reinforcing the picture of a stock that has been rewarded for delivering higher-than-expected profitability while maintaining a robust order pipeline in key segments.
Preclinical research services as a growth driver
Charles River Laboratories is widely recognized as a leading provider of research models and preclinical and clinical support services that help pharmaceutical, biotechnology, and medical device companies bring new therapies to market. Across its business segments, the company offers discovery services, safety assessment, and manufacturing solutions that sit embedded in the drug development process.
In the Discovery and Safety Assessment unit highlighted in the Q2 2026 results, the Book-to-Bill ratio of 1.19 underscores that customers are committing to more work than the company is currently recognizing as revenue. With this ratio above 1.0 for three consecutive quarters, the backlog has grown steadily, offering visibility into future revenue streams and supporting managements confidence in raising the full-year EPS guidance.
Beyond discovery and safety, Charles River Laboratories provides specialized services such as in vivo pharmacology studies, toxicology assessments, and regulatory support, forming an integrated platform that allows clients to outsource critical parts of their preclinical programs. This positioning can be attractive in a world where biopharma companies seek both efficiency and expertise, and the strong recent financial performance suggests that demand for such services has remained resilient.
Representative product: discovery and safety assessment services
One representative offering within Charles River Laboratories portfolio is its integrated discovery and safety assessment service line, which supports early-stage drug projects from target identification through IND-enabling studies. These services bundle capabilities such as in vitro assays, in vivo disease models, toxicology packages, and bioanalytical support, allowing clients to move compounds through the pipeline using a consistent partner and standardized processes.
For global pharmaceutical groups and emerging biotechs alike, the ability to outsource discovery and safety assessment work to a specialized provider like Charles River Laboratories can reduce the need for internal infrastructure investment while giving access to experienced scientists and well-characterized models. The reported Q2 2026 Book-to-Bill ratio of 1.19 in this segment, with three quarters above the 1.0 threshold, indicates that clients continue to sign new projects at a rate exceeding current revenue recognition, supporting medium-term growth.
Stock level and valuation as of the latest close
As of the most recent completed trading session on August 20, 2026, Charles River Labs stock closed around $291.48 on the CBOE, according to MarketScreener, after touching a 52-week intraday high of $294.68 during the day. The prior New York Stock Exchange close cited in news summaries was $290.00 on August 19, 2026, and intraday quotes on August 20, 2026 extended toward $294.93.
At these levels, the companys valuation multiples are elevated relative to several intrinsic value estimates and consensus price targets, but investors have so far been willing to sustain the premium in light of the Q2 2026 earnings beat, the raised full-year EPS guidance of $11.15 to $11.45, and the solid order trends in key service segments. For market participants, the tension between the high headline P/E of 78x at $291.48 and the robust operational metrics will likely remain central to how the stock trades around its recently established 52-week high in the coming weeks.
Go deeper
Read-more: more on Charles River Labs stock performance and earnings developments can be found in the IT Boltwise Q2 2026 overview and the Ad-hoc News 52-week-high report linked above.
Company fact box
Company: Charles River Laboratories International, Inc.
ISIN: US1591881009
Ticker: CRL
Exchange: New York Stock Exchange
Price (as of August 20, 2026, 3:59 p.m. ET): $291.48 USD
Market cap: not specified in the cited sources
Sector / Industry: Healthcare - research and laboratory services
Index membership: S&P 500
